Validation of a selective method for determination of paroxetine in human plasma by LC-MS/MS

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 8, Issue 2, 2005, Pages 340-347

  Massaroti, P ^a   Cassiano, N M ^a   Duarte, L F ^a   Campos, D R ^a   Marchioretto, M A M ^a   Bernasconi, G ^a   Calafatti, S ^a   Barros, F A P ^a   Meurer, Eduardo Cesar ^a,b   Pedrazzoli, J ^a  

^a Universidade Sao Francisco Centro de Ciencias Biologicas e da Saude   (Brazil)

^b UNIVERSIDADE SÃO FRANCISCO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; PAROXETINE;

ACCURACY; ADULT; ANALYTIC METHOD; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DETERMINATION; HUMAN; IONIZATION; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MALE; PLASMA; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS; VOLUNTEER;

ADOLESCENT; ADULT; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, LIQUID; CROSS-OVER STUDIES; HUMANS; MALE; MASS SPECTROMETRY; PAROXETINE;

EID: 27244457756     PISSN: 14821826     EISSN: 14821826     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Boyer, W. F.; Feighner, J. P., an overview of Paroxetine. J Clin Psychiatry. 53: 3-6, 1992.
2. Dechant, K. L.; Clissold, S. P., paroxetine. a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs. 41(2):225-53, 1991.
3. Catterson, M.L.; Preskorn, S.H., pharmacokinetics of selective serotonin reuptake inhibitors: clinical relevance. Pharmacol Toxicol. 78(4):203-8, 1996.
4. Nemeroff, C. B., paroxetine: an overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression. J Clin Psychopharmacol. 13:10S-17S, 1993.
5. Hiemke, C., paroxetine: pharmacokinetics and pharmacodynamics Fortschr Neurol Psychiatr. 62 1:2-8, 1994.
6. (a) Eap, C.B.; Bouchoux, G.; Amey, M.; Cochard, N.; Savary, L.; Baumann, P., simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry. J Chromatogr Sci. Jul;36(7):365-71, 1998.
7. Maurer, H.H.; Bickeboeller-Friedrich, J., screening procedure for detection of antidepressants of the selective serotonin reuptake inhibitor type and their metabolites in urine as part of a modified systematic toxicological analysis procedure using gas chromatography-mass spectrometry. J Anal Toxicol. 24(5):340-7, 2000.
8. (a) Erk, N.; Biryol, I., voltammetric and HPLC techniques for the determination of paroxetine hydrochloride. J Pharmazie. 58(10):699-704, 2003
9. (b) Duverneul, C.; de la Grandmaison, G.L.; de Mazancourt, P.; Alvarez, J.C., a high-performance liquid chromatography method with photodiode-array UV detection for therapeutic drug monitoring of the nontricyclic antidepressant drugs. Ther Drug Monit. 25(5):565-73, 2003,
10. (b) Lopez-Calull, C.; Dominguez, N.; determination of paroxetine in plasma by high-performance liquid chromatography for bioequivalence studies, J Chromatogr B Biomed Sci Appl. 724(2):393-8, 1999.
11. (a) Zhu, Z.; Neirinck, L., high-performance liquid chromatography-mass spectrometry method for the determination of paroxetine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 780(2):295-300, 2002.
12. Juan, H.; Zhiling, Z.; Huande, L. simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). J Chromatogr B Analyt Technol Biomed Life Sci. 820(1):33-9, 2005.
13. Naidong, W.; Eerkes, A. development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometric method for the analysis of paroxetine in human plasma. Biomed Chromatogr. 18(1):28-36, 2004.
14. (a) Federal Register Part. 320: Bioavailability and Bioequivalence Requirements. Food and Drug Administration: Washington, DC, 1985; 154,
15. (b) Food and Drug Administration. Pharmacopeial Fórum 1993; 19: 6501.
16. a) Chapman, J.R. Pratical Organic Mass Spectrometry, 2a ed., 1993.
17. b) Hoffmann, E.; Charette, J.; Stroobant, V. Mass Spectrometry Principles and Applications.
18. c) Watson, J. T. Introduction to Mass Spectrometry, 3a ed., 1997.
19. (a) Ho, E.N.; Yiu, K.C.; Wan, T.S.; Stewart, B.D.; Watkins, K.L. detection of anti-diabetics in equine plasma and urine by liquid chromatography-tandem mass spectrometry. J Chromatogr B Nov 5;811(1):65-73, 2004.
20. (b) Maralikova, B.; Weinmann, W. confirmatory analysis for drugs of abuse in plasma and urine by high-performance liquid chromatography-tandem mass spectrometry with respect to criteria for compound identification. J Chromatogr B 5;811(1):21-30. 2004.
21. (c) Taylor, P.J.; Forrest, K.K.; Landsberg, P.G.; Mitchell, C.; Pillans, P.I. The measurement of nicotine in human plasma by high-performance liquid chromatography-electrospray-tandem mass spectrometry Ther Drug Monit. Oct; 26(5):563-8, 2004.